Related Experiment Videos
Paclitaxel changes sympathetic control of blood pressure
E Ekholm1, V Rantanen, K Antila
1Department of Obstetrics and Gynaecology, University of Turku, Finland.
European Journal of Cancer (Oxford, England : 1990)
|August 1, 1997
Summary
Paclitaxel treatment for ovarian and breast cancer did not cause cardiac autonomic neuropathy. However, it did alter blood pressure variability, suggesting an effect on sympathetic control.
Area of Science:
- Oncology
- Cardiology
- Autonomic Neuroscience
Background:
- Paclitaxel is a key chemotherapy agent for ovarian and breast cancers.
- Concerns exist regarding paclitaxel's impact on cardiovascular function.
- Autonomic cardiovascular control is crucial for maintaining cardiovascular homeostasis.
Purpose of the Study:
- To investigate the effects of paclitaxel on autonomic cardiovascular control in cancer patients.
- To assess changes in heart rate and blood pressure variability.
- To evaluate baroreflex sensitivity before and after paclitaxel treatment.
Main Methods:
- Autonomic cardiovascular function tests were performed on 18 women before and after paclitaxel treatment.
- Measurements included heart rate and blood pressure variability.
- Baroreflex sensitivity was assessed non-invasively using the Valsalva maneuver.
Main Results:
- Paclitaxel did not alter resting heart rate variability compared to baseline.
- A decrease in medium frequency blood pressure variability was observed post-treatment.
- Paclitaxel did not impair heart rate or blood pressure responses during autonomic function tests.
Conclusions:
- Paclitaxel treatment appears to affect sympathetic control of blood pressure.
- The findings suggest paclitaxel does not precipitate autonomic cardiac neuropathy.
- Further research may clarify the long-term cardiovascular implications of paclitaxel therapy.